Literature DB >> 15715088

Extracellular deposits of A beta produced in cultures of Alzheimer disease brain vascular smooth muscle cells.

Janusz Frackowiak1, Anna Potempska, Harry LeVine, Taraneh Haske, Dennis Dickson, Bozena Mazur-Kolecka.   

Abstract

Alzheimer disease (AD) and Down syndrome (DS) brains contain deposits of amyloid-beta peptide that are located extracellularly in the neuropil and in blood vessels walls. A small fraction of brain Abeta is detected intracellularly in neurons, smooth muscle cells, and microglia. The roles of these extracellular and intracellular pools of Abeta in pathogenesis of AD-type dementia are controversial. Cell culture models of vascular amyloidosis-beta revealed intracellular, but not extracellular deposition of Abeta. Here we demonstrate for the first time, formation of extracellular deposits of Abeta in primary cultures of vascular smooth muscle cells isolated from AD cases with cerebrovascular amyloid angiopathy. Extracellular Abeta deposition required the use of cultures that produced high quantities of Abeta, which contained at least 50% of cells forming intracellular Abeta deposits, and providing extracellular matrix proteins. During 12 days of culture in this system, we observed accumulation of nonfibrillar, granular deposits in extracellular matrix, similar to early stages of vascular amyloidogenesis in vivo. This is a valuable system to study the effects of various potential amyloidogenic factors on formation of extracellular Abeta deposits.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15715088     DOI: 10.1093/jnen/64.1.82

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  7 in total

Review 1.  Genetic animal models of cerebral vasculopathies.

Authors:  Jeong Hyun Lee; Brian J Bacskai; Cenk Ayata
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

2.  Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance.

Authors:  Tristan Bolmont; Florent Haiss; Daniel Eicke; Rebecca Radde; Chester A Mathis; William E Klunk; Shinichi Kohsaka; Mathias Jucker; Michael E Calhoun
Journal:  J Neurosci       Date:  2008-04-16       Impact factor: 6.167

Review 3.  Endothelial LRP1 - A Potential Target for the Treatment of Alzheimer's Disease : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.

Authors:  Steffen E Storck; Claus U Pietrzik
Journal:  Pharm Res       Date:  2017-09-25       Impact factor: 4.200

4.  Partial loss of endothelial nitric oxide leads to increased cerebrovascular beta amyloid.

Authors:  Susan A Austin; Zvonimir S Katusic
Journal:  J Cereb Blood Flow Metab       Date:  2019-01-07       Impact factor: 6.200

5.  Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease.

Authors:  J Chapuis; D Hot; F Hansmannel; O Kerdraon; S Ferreira; C Hubans; C A Maurage; L Huot; F Bensemain; G Laumet; A M Ayral; N Fievet; J J Hauw; S T DeKosky; Y Lemoine; T Iwatsubo; F Wavrant-Devrièze; J F Dartigues; C Tzourio; L Buée; F Pasquier; C Berr; D Mann; C Lendon; A Alpérovitch; M I Kamboh; P Amouyel; J C Lambert
Journal:  Mol Psychiatry       Date:  2009-02-10       Impact factor: 15.992

6.  The Blood-Brain Barrier in Alzheimer's Disease.

Authors:  Steffen E Storck; Anika M S Hartz; Claus U Pietrzik
Journal:  Handb Exp Pharmacol       Date:  2022

7.  Mitochondrial oxygen consumption deficits in skeletal muscle isolated from an Alzheimer's disease-relevant murine model.

Authors:  Rosemary A Schuh; Kathryn C Jackson; Anna E Schlappal; Espen E Spangenburg; Christopher W Ward; Ji H Park; Natalie Dugger; Guo Li Shi; Paul S Fishman
Journal:  BMC Neurosci       Date:  2014-02-13       Impact factor: 3.288

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.